At the beginning of year, their projections were $20 million for bepreve sales. Their first quarter actual sales for bepreve was $0.5 million. I think you are correct actual bepreve sales are well below their projections. 2 nd quarter i think their bepreve sales will be about $1.0 million. We will see.
That's funny, I have some other biotech's that are down roughly the same percentage recently and I don't think they sell Bepreve. Actually some biotech's are at or below cash value which sometimes is a pretty good bottom indicator for some. I think making presumptions like that is a little bit limited. Take care.